On March 27, 2019 TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and, through our license to Santen Pharmaceutical Co. Ltd., wet age-related macular degeneration, reported that preclinical data from TRC105 and TRC253, as well as Phase 2 clinical data from TRC102, will be presented at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting, to be held from March 29 to April 3, 2019, in Philadelphia, PA (Press release, Tracon Pharmaceuticals, MAR 27, 2019, View Source [SID1234534674]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Mark Schoonderwoerd and colleagues from Leiden University will present a poster featuring data from preclinical studies of TRC105 and PD-1 checkpoint inhibitors. The presentation details are as follows:
Poster Title: Synergistic inhibition of cancer invasion and metastasis by combined anti-PD1-TRC105-mediated Endoglin targeting on cancer-associated fibroblasts and endothelial cells
Abstract Link: View Source!/6812/presentation/3044
Session Category: Combination Approaches to Novel Therapies
Location: Section 12, Poster Board 291/12
Date: Sunday, March 31, 2019
Time: 1:00pm – 5:00pm EDT
Dr. Tammy Bush and colleagues from Janssen Research and Development will present a poster featuring preclinical data from TRC253, a small molecule antagonist of mutant and wild-type androgen receptor. The presentation details are as follows:
Poster Title: Antitumor activity of JNJ-63576253 (TRC253), a small molecule antagonist of F877L mutant and wild-type androgen receptor
Abstract Link: View Source!/6812/presentation/6162
Session Category: Novel Therapeutics and Pathways
Location: Section 14, Poster Board 2179/1
Date: Monday, April 1, 2019
Time: 1:00pm – 5:00pm EDT
Dr. Geraldine Coyne and colleagues from the National Cancer Institute will present a poster featuring data from the Phase 2 clinical trial of TRC102 and Temodar (temozolomide) in subjects with colorectal cancer. The presentation details are as follows:
Poster Title: A Phase II trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed metastatic colorectal carcinoma
Abstract Link: Late-Breaking Abstracts are embargoed until March 29, 2019
Session Category: Late-Breaking Research – Molecular and Cellular Biology/Genetics 2
Location: Section 41, Poster Board LB-293/10
Date: Wednesday, April 3, 2019
Time: 8:00am – 12:00pm EDT
Posters will be available on the company’s website following presentation.
About TRC105 (carotuximab)
TRC105, the oncology formulation of carotuximab, is a novel, clinical stage antibody to endoglin, a protein overexpressed on proliferating endothelial cells that is essential for angiogenesis, the process of new blood vessel formation. TRC105 is currently being studied in the pivotal Phase 3 TAPPAS trial in patients with angiosarcoma as well as multiple Phase 1 and Phase 2 clinical trials in other tumor types. TRC105 has received orphan designation for the treatment of soft tissue sarcoma in both the US and EU. The ophthalmic formulation of TRC105, DE-122, is currently being studied in the randomized Phase 2 AVANTE trial in patients with wet AMD. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.
About TRC253
TRC253 is a novel, orally bioavailable small molecule that is a potent, high affinity competitive inhibitor of the androgen receptor (AR) and AR mutations, including the F877L mutation. The AR F877L mutation results in an alteration in the AR ligand binding domain that confers resistance to therapies for prostate cancer. Therapies targeting the AR have demonstrated clinical efficacy by extending time to disease progression, and in some cases, the survival of patients with metastatic castration-resistant prostate cancer. However, resistance to these agents is often observed and several molecular mechanisms of resistance have been identified, including gene amplification, overexpression, alternative splicing, and point mutation of the AR. TRC253 is currently being studied in a Phase 1/2 clinical trial in prostate cancer. For more information about the clinical trial, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php
About TRC102
TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center. For more information about the clinical trials, please visit TRACON’s website at www.traconpharma.com/clinical_trials.php.